Goldstein Advisors LLC Sells 220 Shares of Johnson & Johnson (NYSE:JNJ)

Goldstein Advisors LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 4.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,275 shares of the company’s stock after selling 220 shares during the quarter. Goldstein Advisors LLC’s holdings in Johnson & Johnson were worth $618,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Endeavor Private Wealth Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $50,000. Raleigh Capital Management Inc. increased its holdings in shares of Johnson & Johnson by 48.3% in the fourth quarter. Raleigh Capital Management Inc. now owns 14,773 shares of the company’s stock valued at $2,136,000 after purchasing an additional 4,810 shares during the last quarter. Asset Planning Services Inc. LA ADV lifted its stake in shares of Johnson & Johnson by 3.1% during the 4th quarter. Asset Planning Services Inc. LA ADV now owns 37,224 shares of the company’s stock worth $5,383,000 after buying an additional 1,120 shares during the last quarter. True North Advisors LLC boosted its holdings in shares of Johnson & Johnson by 2.9% during the 4th quarter. True North Advisors LLC now owns 9,046 shares of the company’s stock worth $1,308,000 after buying an additional 253 shares during the period. Finally, Janney Montgomery Scott LLC grew its stake in Johnson & Johnson by 10.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 1,292,787 shares of the company’s stock valued at $186,963,000 after buying an additional 120,815 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Guggenheim upped their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Morgan Stanley dropped their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday. Finally, Raymond James dropped their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $170.06.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $146.76 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock’s 50-day simple moving average is $147.85 and its 200 day simple moving average is $155.99. The firm has a market capitalization of $353.34 billion, a PE ratio of 22.07, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22,438,500 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company posted $2.29 EPS. On average, analysts anticipate that Johnson & Johnson will post 10.56 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.